Literature DB >> 8383517

The lipolytic effect of beta 1- and beta 2-adrenoceptor activation in healthy human volunteers.

C A Haffner1, M J Kendall, S Maxwell, B Hughes.   

Abstract

1. We investigated the effect of activation beta 1- and beta 2-adrenoceptors on the process of lipolysis in human volunteers. Ten male subjects underwent a single-blind randomized cross-over trial using infusions of terbutaline (a specific beta 2-adrenoceptor agonist), xamoterol (a partial beta 1-agonist with beta 2-adrenoceptor blocking activity) and saline (placebo control). The effect of these infusions on plasma potassium, glucose, free fatty acids (FFA) (total and individual) and insulin levels was studied. 2. Terbutaline infusion induced a significant rise in plasma glucose and a fall in plasma potassium in keeping with its beta 2-adrenoceptor stimulant properties. Xamoterol infusion had no significant effect on these values. Terbutaline infusion caused a greater rise in total and individual FFA than xamoterol, but both effects were significantly different from placebo. 3. The possible reasons for these results and their implications on the beta-adrenergic control of lipolysis are discussed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8383517      PMCID: PMC1381487          DOI: 10.1111/j.1365-2125.1993.tb05667.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  20 in total

1.  Human fat cell beta-adrenergic receptors: beta-agonist-dependent lipolytic responses and characterization of beta-adrenergic binding sites on human fat cell membranes with highly selective beta 1-antagonists.

Authors:  P Mauriège; G De Pergola; M Berlan; M Lafontan
Journal:  J Lipid Res       Date:  1988-05       Impact factor: 5.922

2.  Characterization of the beta-adrenoceptor of the adipose cell of the rat.

Authors:  S Tan; P B Curtis-Prior
Journal:  Int J Obes       Date:  1983

Review 3.  Adrenergic receptors in man: direct identification, physiologic regulation, and clinical alterations.

Authors:  H J Motulsky; P A Insel
Journal:  N Engl J Med       Date:  1982-07-01       Impact factor: 91.245

4.  Pharmacokinetics of xamoterol after intravenous and oral administration to volunteers.

Authors:  W Bastain; M J Boyce; L E Stafford; P B Morton; D A Clarke; H F Marlow
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 5.  New directions in asthma: some cause for concern.

Authors:  A Abbott
Journal:  Trends Pharmacol Sci       Date:  1988-05       Impact factor: 14.819

6.  The cardiovascular effects of ICI 118,587: A beta 1-adrenoceptor partial agonist.

Authors:  A Nuttall; H M Snow
Journal:  Br J Pharmacol       Date:  1982-10       Impact factor: 8.739

7.  Cardioselectivity, kinetics, hemodynamics, and metabolic effects of xamoterol.

Authors:  G Jennings; A Bobik; C Oddie; R Restall
Journal:  Clin Pharmacol Ther       Date:  1984-05       Impact factor: 6.875

8.  The rat lipolytic beta-adrenoceptor: studies using novel beta-adrenoceptor agonists.

Authors:  C Wilson; S Wilson; V Piercy; M V Sennitt; J R Arch
Journal:  Eur J Pharmacol       Date:  1984-05-04       Impact factor: 4.432

9.  The influence of beta-adrenoceptor blockade on the lipolytic response to exercise.

Authors:  P E Hall; S R Smith; D B Jack; M J Kendall
Journal:  J Clin Pharm Ther       Date:  1987-04       Impact factor: 2.512

10.  Metabolic and haemodynamic effects and pharmacokinetics of a new selective beta 1-adrenoceptor agonist, prenalterol, in man.

Authors:  O Rönn; E Fellenius; C Graffner; G Johnsson; P Lundborg; L Svensson
Journal:  Eur J Clin Pharmacol       Date:  1980-02       Impact factor: 2.953

View more
  4 in total

Review 1.  Exercise metabolism and beta-blocker therapy. An update.

Authors:  A Head
Journal:  Sports Med       Date:  1999-02       Impact factor: 11.136

2.  Association analyses of adrenergic receptor polymorphisms with obesity and metabolic alterations.

Authors:  John J Lima; Hua Feng; Laurie Duckworth; Jianwei Wang; James E Sylvester; Niranjan Kissoon; Hardesh Garg
Journal:  Metabolism       Date:  2007-06       Impact factor: 8.694

3.  Exercise metabolism in healthy volunteers taking atenolol, high and low doses of metoprolol CR/Z0K, and placebo.

Authors:  A Head; S Maxwell; M J Kendall; C Eagles
Journal:  Br J Clin Pharmacol       Date:  1994-12       Impact factor: 4.335

4.  Association of ADRB2 polymorphism with triglyceride levels in Tongans.

Authors:  Izumi Naka; Jun Ohashi; Ryosuke Kimura; Tsukasa Inaoka; Yasuhiro Matsumura
Journal:  Lipids Health Dis       Date:  2013-07-23       Impact factor: 3.876

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.